Last updated: September 14, 2026
Fenofibric acid delayed-release capsules are an established generic opportunity centered on formulation execution rather than active-ingredient novelty. The commercial priorities are reliable delayed release, bioequivalence to the reference product, low manufacturing cost, broad excipient compatibility, and differentiated presentation. The reference product, Trilipix, was approved by the FDA in 2008 in 45 mg and 135 mg strengths. Current opportunities include generic supply, lactose-free or reduced-allergen formulations, improved capsule robustness, contract development and manufacturing, and formulation platforms that support additional modified-release products.
What is fenofibric acid delayed-release?
Fenofibric acid is the active metabolite of fenofibrate and is marketed as a delayed-release oral capsule. Trilipix was developed for treatment of dyslipidemia, including hypertriglyceridemia and mixed dyslipidemia, and for use with statin therapy in selected patients. The product is available in 45 mg and 135 mg strengths.[1]
The delayed-release design separates the dosage form from immediate exposure in the stomach. Product performance depends on:
- Granule or pellet size distribution
- Drug loading and powder flow
- Polymer selection
- Coating weight gain
- Acid resistance
- Buffer-stage release
- Capsule-fill uniformity
- Stability under humidity and heat
The product label permits administration without regard to meals, a commercial advantage over older fenofibrate formulations that had more pronounced food-dependent absorption.[1]
What excipients are used in fenofibric acid delayed-release capsules?
The reference and generic products use excipient systems that support powder processing, drug dispersion, capsule manufacture, and delayed release. Exact formulations vary by manufacturer and are controlled by the approved product dossier.
Common functional excipient classes include:
| Excipient function |
Representative materials |
Commercial role |
| Diluent |
Lactose monohydrate, microcrystalline cellulose |
Controls fill weight and improves processability |
| Binder |
Hydroxypropyl cellulose, hypromellose |
Improves granule strength and drug distribution |
| Disintegrant |
Crospovidone, croscarmellose sodium |
Promotes release after the delayed-release barrier dissolves |
| Lubricant |
Magnesium stearate |
Reduces tooling and capsule-filling friction |
| Surfactant or wetting agent |
Sodium lauryl sulfate or comparable surfactants |
Improves wetting of poorly soluble drug material |
| Coating polymer |
Methacrylic acid copolymers, hypromellose derivatives, or other enteric polymers |
Controls gastric resistance and intestinal release |
| Anti-tacking agent |
Talc, colloidal silicon dioxide |
Stabilizes coating operations |
| Capsule shell |
Gelatin or hypromellose |
Provides the final oral dosage form |
A generic manufacturer does not need to duplicate every inactive ingredient in Trilipix. It must demonstrate pharmaceutical equivalence and bioequivalence while satisfying FDA quality requirements. The FDA identifies inactive ingredients through product labeling and the Inactive Ingredient Database, but the database does not establish that every listed excipient is interchangeable at every dose or route of administration.[2]
Which excipient attributes are commercially important?
The highest-value excipient decisions concern release control and manufacturability. A coating polymer that provides strong acid resistance may require higher coating weight, longer processing time, or more aggressive drying. A lower-cost polymer may create batch-to-batch variability or delayed dissolution in the intestinal stage.
The preferred formulation must meet four practical targets:
- Minimal drug release in the acidic stage.
- Prompt and reproducible release after pH transition.
- Uniform exposure across capsule strengths.
- Stable dissolution after long-term and accelerated storage.
Surfactant use requires particular control. Fenofibric acid has limited aqueous solubility, so wetting agents can improve dissolution. Excess surfactant, however, can alter the release profile, increase sensitivity to humidity, or complicate capsule-shell compatibility.
What formulation strategies can improve fenofibric acid delayed release?
Enteric-coated multiparticulates
Multiparticulate systems use drug-loaded pellets or granules coated with an enteric polymer. They can provide narrower release variability than a single coated tablet and permit independent optimization of drug loading and coating thickness.
Commercial advantages include:
- Better control of coating uniformity
- Lower risk of dose dumping from a single-unit failure
- Potential for capsule filling at multiple strengths
- Flexibility for future sprinkle or sachet presentations
The main disadvantages are higher process complexity, greater equipment requirements, and increased coating-material consumption.
Direct-blend or granulated capsule fills
A simpler capsule-fill platform can reduce capital cost and shorten manufacturing cycles. This approach is attractive for high-volume generic supply if the formulation provides adequate content uniformity and dissolution.
The principal risk is inadequate distribution of low-dose active material, especially in the 45 mg strength. Granulation, ordered mixing, or engineered drug particles may be required to prevent segregation.
Taste-masked or sprinkle-compatible systems
A sprinkle capsule could expand use among patients with swallowing difficulty. The commercial value depends on maintaining delayed release after opening the capsule and mixing the contents with an approved food vehicle. This would require product-specific development and regulatory support. A conventional delayed-release capsule should not be assumed to have sprinkle compatibility.
Lactose-free and allergen-conscious formulations
Lactose-free products could differentiate a generic portfolio where the reference or competing products use lactose. Microcrystalline cellulose, mannitol, or selected dibasic calcium phosphate grades could replace lactose, but each substitution affects density, flow, moisture response, and dissolution.
Hypromellose capsules may offer an alternative to gelatin for vegetarian, religious, or supply-chain reasons. They also have different moisture-transfer characteristics and may require changes to packaging and stability controls.
What FDA regulatory status applies to fenofibric acid delayed-release?
Fenofibric acid delayed-release capsules are approved through the FDA’s abbreviated new drug application pathway when a generic applicant demonstrates pharmaceutical equivalence and bioequivalence to the reference-listed drug. Trilipix was approved on December 15, 2008, in 45 mg and 135 mg delayed-release capsule strengths.[1]
The relevant regulatory framework includes:
- ANDA approval under section 505(j) of the Federal Food, Drug, and Cosmetic Act
- Pharmaceutical-equivalence testing
- In vitro dissolution testing
- Bioequivalence studies or FDA-accepted waivers where applicable
- Stability studies under ICH conditions
- Current Good Manufacturing Practice compliance
- Labeling that identifies inactive ingredients and administration instructions
A formulation change that materially alters release, dosage form, strength, or clinical performance may require a prior-approval supplement or a separate 505(b)(2) development program rather than a routine ANDA.
What is the Orange Book status of fenofibric acid delayed-release?
The Orange Book identifies the reference-listed drug, approved strengths, dosage form, therapeutic equivalence codes, and any patents or exclusivity periods relevant to generic approval.[3] Trilipix’s core regulatory exclusivity has expired. Generic manufacturers therefore compete primarily on manufacturing economics, supply reliability, wholesaler access, and formulation quality.
The commercial significance of Orange Book review is concentrated in three areas:
| Issue |
Impact on a new entrant |
| Reference-listed drug status |
Determines the product used for generic bioequivalence |
| Listed patents |
Determines whether a Paragraph IV certification or later launch date is required |
| Therapeutic-equivalence rating |
Influences substitution and payer acceptance |
The original delayed-release formulation patent estate was historically associated with Abbott Laboratories and fenofibric-acid pharmaceutical composition claims. Core U.S. composition and formulation patents from the early development period, including U.S. Patent No. 6,589,552, have reached the end of their ordinary patent terms.[4] Current launch planning should rely on the live Orange Book record and any later-listed patents, not on historical patent listings.
When did fenofibric acid delayed-release lose exclusivity?
The principal market exclusivity period ended years ago. Trilipix’s 2008 approval date placed its standard new-drug exclusivity period in the 2008-2011 window. Any patent protection extending beyond that period was separate from FDA exclusivity and depended on the specific patent claims and term adjustments.
A simplified timeline is:
| Date |
Event |
| December 15, 2008 |
FDA approval of Trilipix delayed-release capsules |
| 2011 |
Standard three-year regulatory exclusivity period expired |
| Early 2020s |
Core early-generation formulation patent terms reached or passed ordinary expiry |
| Current market |
Generic and multisource competition is the primary commercial model |
Are Paragraph IV challenges or litigation material?
Paragraph IV risk is generally less significant for an old, multisource product than for a newly approved modified-release medicine. A new ANDA applicant still must review all listed patents and certify appropriately. A Paragraph IV certification can trigger patent litigation, a 30-month stay, or a negotiated launch date if a live patent is listed.
For fenofibric acid delayed-release capsules, the greater current risks are operational:
- Failure to match dissolution across pH stages
- Inadequate bioequivalence
- Manufacturing deviations involving coating weight
- Supply interruptions for enteric polymers or capsule shells
- Product-specific labeling differences
- FDA observations involving process validation or data integrity
No biosimilar pathway applies because fenofibric acid is a small-molecule active ingredient, not a biologic. The relevant competitive threat is generic substitution rather than biosimilar interchangeability.
How strong is the patent estate for fenofibric acid delayed-release?
The historical patent estate is weaker than the commercial formulation barrier. Core molecule and early delayed-release claims are old, while residual value may remain in:
- Specific polymer combinations
- Coating-layer architecture
- Multiparticulate release systems
- Manufacturing processes
- Low-dose uniformity controls
- Stabilized compositions
- Alternative capsule materials
- Sprinkle or food-mixed presentations
These opportunities require claim construction and freedom-to-operate analysis. An excipient substitution can avoid a composition claim but still infringe a process or release-profile claim. A design-around must consider literal infringement, equivalents, prosecution history, and regulatory disclosure.
What commercial opportunities exist for excipient suppliers and manufacturers?
Generic product development
The largest opportunity is a cost-efficient 45 mg and 135 mg capsule platform. A common granulation or pellet process that supports both strengths can reduce validation burden and improve inventory management.
Excipient supply
Excipient suppliers can compete through:
- Low-variability enteric polymers
- Direct-compression grades
- Low-moisture capsule shells
- Improved surfactant concentrates
- Spray-dried or engineered diluents
- Functional coating systems with lower weight gain
The buyer’s value equation includes total process cost, not only price per kilogram. A more expensive polymer may lower coating time, rejection rates, and dissolution failures.
Contract development and manufacturing
CDMOs with fluid-bed coating, multiparticulate processing, and modified-release analytical capability can offer a complete development package. The strongest providers will control critical quality attributes from preformulation through commercial-scale coating.
Portfolio expansion
A developer with a validated enteric multiparticulate platform can apply the process to other poorly soluble small molecules. The strategic value is therefore broader than one fenofibric acid product, provided platform claims and regulatory comparability are managed carefully.
How does fenofibric acid compare with fenofibrate formulations?
Fenofibric acid delayed-release capsules are designed to avoid the pronounced meal dependence associated with some older fenofibrate products. Fenofibrate products have used micronized, nanocrystal, and other absorption-enhancing technologies. Fenofibric acid products compete through dosing convenience and formulation consistency rather than a novel active-moiety mechanism.
| Attribute |
Fenofibric acid delayed release |
Fenofibrate formulations |
| Active moiety |
Fenofibric acid |
Fenofibrate |
| Dosage form |
Delayed-release capsule |
Multiple forms, including tablets and capsules |
| Food instruction |
Trilipix label permits administration without regard to meals |
Depends on product formulation |
| Generic development |
Focus on delayed-release dissolution and bioequivalence |
Focus varies by formulation and absorption technology |
| Biosimilar risk |
None |
None |
| Main commercial barrier |
Release control and process reproducibility |
Product-specific absorption and formulation performance |
What generic launch risks exist?
A successful launch requires more than patent clearance. Key risks include:
- Weak initial supply commitments
- Failure to qualify two sources for critical coating materials
- Inability to reproduce the reference dissolution profile
- Excessive capsule-fill weight
- Humidity-related shell or granule changes
- Retail substitution delays caused by therapeutic-equivalence status
- Price erosion from multiple approved ANDAs
- Limited commercial differentiation in a mature lipid-lowering market
Revenue exposure is normally modest for an individual generic because fenofibric acid is an older product with established competition. The opportunity improves when the developer has a low-cost platform, dependable supply, and access to institutional, Medicaid, or large pharmacy customers.
Key Takeaways
- Fenofibric acid delayed-release capsules are a mature small-molecule generic opportunity.
- The commercial value is concentrated in release performance, manufacturing yield, and supply reliability.
- The principal dosage strengths are 45 mg and 135 mg.
- Enteric polymers, wetting agents, diluents, capsule materials, and coating-process controls determine product performance.
- Lactose-free, hypromellose-capsule, multiparticulate, and sprinkle-compatible concepts offer potential differentiation.
- Core early-generation patent protection and FDA exclusivity have expired, but live Orange Book listings and later formulation claims must be reviewed before launch.
- Patent risk is lower than formulation and bioequivalence risk for most current entrants.
- No biosimilar pathway applies.
- The strongest business case is a common, scalable delayed-release platform that supports both strengths and additional modified-release products.
FAQs
Can fenofibric acid delayed-release capsules use different excipients from Trilipix?
Yes. A generic product can use different inactive ingredients if it meets applicable pharmaceutical-equivalence, bioequivalence, quality, labeling, and safety requirements.
Is an enteric coating required for every fenofibric acid delayed-release product?
A product must achieve the approved delayed-release performance, but the exact polymer and coating architecture can differ. The regulatory standard is product performance, not duplication of the reference formulation.
Can lactose be removed from a fenofibric acid delayed-release formulation?
Yes, but replacing lactose can change powder density, flow, compaction, moisture response, and dissolution. A lactose-free formulation requires full development and stability evaluation.
Is fenofibric acid delayed release suitable for a 505(b)(2) product?
A materially different dosage form, administration method, or release system may fit a 505(b)(2) strategy. A conventional equivalent generic is generally pursued through an ANDA.
What is the most defensible formulation differentiation?
A robust multiparticulate release system with reproducible pH-stage dissolution, low moisture sensitivity, scalable coating, and a clear patient-use advantage offers the strongest commercial differentiation.
References
- U.S. Food and Drug Administration. (2008). Trilipix (fenofibric acid) delayed-release capsules: Prescribing information.
- U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Patent No. 6,589,552. (2003). Fenofibric acid pharmaceutical compositions. United States Patent and Trademark Office.
- International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products.
- U.S. Food and Drug Administration. (2013). Guidance for industry: Bioavailability and bioequivalence studies submitted in NDAs or INDs: General considerations.
